As post-WWII baby boomer approaching age 80, Anti-Aging Regenerative Cosmetology (AARC) has been developed and patented for beautifying and strengthening the human body using live cells; to enhance the appearance and function of various bodily parts to provide health and aestheticism of human being throughout life. It is a combined cosmetic and preventive medicine to intervene with and to correct the undesirable phenotypic expression of aging. The intrinsic properties of myoblasts and foreskin fibroblasts in development and regeneration are harnessed to formulate a genetic cell therapy program which is safe and efficacious as previously been tested in FDA Phase III clinical trials. Myoblasts are selected for strength development and foreskin fibroblasts for tenacity and smooth-to-the-touch. Both cell types are highly mitotic and non-carcinogenic. In additional to providing large quantities of nuclei as regenerative gene medicine, and of mitochondria as energy generators, myoblasts secret tumor necrosis factor alpha (TNF-α) for skin whitening and melanoma prevention. Myoblasts, because of their small size, spindle shape, and resilience, grow readily on collagen and laminin within wrinkles of skin surfaces, thus enhancing the color, luster, and texture of the skin “plated” with them. Alternatively, they can be injected subcutaneously as cell filler to reduce wrinkles. Intramuscular injection of myoblasts can augment the size, shape, consistency, tone, and strength of muscle groups, improving the lines, contours, and vitality to sculpt a youthful appearance. By improving cell genetics and organ functions, the program holds promise to sustain the human subject in good health and appearance, with a good quality of life and life prolongation.
References
[1]
Campisi, J., Kapahi, P., Lithgow, G.J., et al. (2019) From Discoveries in Ageing Research to Therapeutics for Healthy Ageing. Nature, 571, 182-192. https://doi.org/10.1038/s41586-019-1365-2
[2]
Law, P.K., Bertorini, T., Goodwin, T.G., et al. (1990) Dystrophin Production Induced by Myoblast Transfer Therapy in Duchenne Muscular Dystrophy. The Lancet, 336, 114-115. https://doi.org/10.1016/0140-6736(90)91628-N
[3]
Law, P.K., Law, D.M., Ye, L., et al. (2019) Myoblasts Provide Safe and Effective Treatments for Hereditary Muscular Dystrophies, Cardiomyopathies, Type 2 Diabetes, Solid Tumors and Aging. In: Haider, K.H. and Aziz, S., Eds., Stem Cells—From Hype to Real Hope, Walter de Gruyter GmbH, Berlin, 71-97. https://doi.org/10.1515/9783110587043-004
[4]
Law, P.K., Li, W., Song, Q., et al. (2022) Chapter 22. Myoblast Therapies Constitute a Safe and Efficacious Platform Technology of Regenerative Medicine for the Human Health Industry. In: Haider, K.H. and Aziz, S., Eds., Stem Cells Latest Advances, Springer Nature GmbH, Berlin, 1-66. https://doi.org/10.1007/978-981-16-6016-0_34-1
[5]
Marks, P. and Gottlieb, S. (2018) Balancing Safety and Innovation for Cell-Based Regenerative Medicine. The New England Journal of Medicine, 378, 954-959. https://doi.org/10.1056/NEJMsr1715626
Law, P.K. (1995) Methods for Human Myoblast Culture and Transplantation. In: Recordi, C., Ed., Methods in Cell Transplantation, RG Landes Co., Austin, Sec. H5, 707-730.
[8]
Law, P.K. and Law, D.M. (2011) Human Myoblast Genome Therapies and Devices in Regenerative Medicine. Recent Patents on Regenerative Medicine, 1, 88-117. https://doi.org/10.2174/2210297311101010088
[9]
Mimeault, M. and Batra, S.K. (2009) Recent Insights into the Molecular Mechanisms Involved in Aging and the Malignant Transformation of Adult Stem/Progenitor Cells and Their Therapeutic Implications. Ageing Research Reviews, 8, 94-112. https://doi.org/10.1016/j.arr.2008.12.001
[10]
Law, P.K., Saito, A. and Fleischer, S. (1983) Ultrastructural Changes in Muscle and Motor Endplate of the Dystrophic Mouse. Experimental Neurology, 80, 361-382. https://doi.org/10.1016/0014-4886(83)90289-3
[11]
Sullivan, D. (2021) “Whole-Body Mitochondrial Transfusion” Start-Up Lands Funding. Longevity Technology, January 28, 2021.
[12]
Law, P.K. (2016) Disease Prevention and Alleviation by Human Myoblast Transplantation. Open Journal of Regenerative Medicine, 5, 25-43. https://doi.org/10.4236/ojrm.2016.52003
[13]
Law, P.K. (2017) Crime against Humanity. Open Journal of Regenerative Medicine, 6, 35-645. https://doi.org/10.4236/ojrm.2017.64004
[14]
Law, P.K., Law, D.M., Lu, P., et al. (2004) The World’s First Myoblast Study of Type II Diabetic Patients. Business Briefing: North American Pharmacotherapy No. 2.
[15]
Peng, Y., Xuan, M., Leung, V.Y.L. and Cheng, B. (2015) Stem Cells and Aberrant Signaling of Molecular Systems in Skin Aging. Ageing Research Reviews, 19, 8-21. https://doi.org/10.1016/j.arr.2014.10.006
[16]
Godic, A. (2019) The Role of Stem Cells in Anti-Aging Medicine. Clinics in Dermatology, 37, 320-325. https://doi.org/10.1016/j.clindermatol.2019.04.011
[17]
Di Donna, S., Mamchaoui, K., Cooper, R.N., et al. (2003) Telomerase Can Extend the Proliferative Capacity of Human Myoblasts but Does Not Lead to Their Immortalization. Molecular Cancer Research, 1, 643-653.
[18]
Xiong, M., Zhang, Q., Hu, W., et al. (2021) The Novel Mechanisms and Applications of Exosomes in Dermatology and Cutaneous Medical Aesthetics. Pharmacological Research, 166, Article ID: 105490. https://doi.org/10.1016/j.phrs.2021.105490
[19]
Giri, S., Machens, H.-G. and Bader, A. (2019) Therapeutic Potential of Endogenous Stem Cells and Cellular Factors for Scar-Free Skin Regeneration. Drug Discovery Today, 24, 69-84. https://doi.org/10.1016/j.drudis.2018.10.014
[20]
Law, P.K., Sim, E.K.W., Haider, Kh.H., et al. (2004) Myoblast Genome Therapy and the Regenerative Heart. In: Kipshidze, N.N. and Serruys, P.W., Eds., Handbook of Cardiovascular Cell Transplantation, Martin Dunitz, London, 241-258.
[21]
Ye, L., Lee, K.O., Su, L.P., et al. (2009) Skeletal Myoblast Transplantation for Attenuation of Hyperglycaemia, Hyperinsulinaemia and Glucose Intolerance in a Mouse Model of Type 2 Diabetes Mellitus. Diabetologia, 52, 1925-1934. https://doi.org/10.1007/s00125-009-1421-9
[22]
Ma, J.H., Su, L.P., Zhu, J., et al. (2013) Skeletal Myoblast Transplantation on Gene Expression Profiles of Insulin Signaling Pathway and Mitochondrial Biogenesis and Function in Skeletal Muscle. Diabetes Research and Clinical Practice, 102, 43-52. https://doi.org/10.1016/j.diabres.2013.08.006
[23]
Law, P.K. (2002) Concomitant Angiogenesis/Myogenesis in the Regenerative Heart. Business Briefing: Future Drug Discovery, Genomics: 64-67, October 2002.
[24]
Law, P.K., Haider, K., Fang, G., et al. (2004) Human VEGF165-Myoblasts Produce Concomitant Angiogenesis/Myogenesis in the Regenerative Heart. Molecular and Cellular Biochemistry, 263, 173-178. https://doi.org/10.1023/B:MCBI.0000041859.60354.f5
[25]
Ye, L., Haider, H.Kh., Jiang, S., et al. (2003) High Efficiency Transduction of Human VEGF165 into Human Skeletal Myoblasts: In Vitro Studies. Experimental & Molecular Medicine, 35, 412-420. https://doi.org/10.1038/emm.2003.54
[26]
Ye, L., Haider, H.Kh., Jiang, S., et al. (2005) In Vitro Functional Assessment of Human Skeletal Myoblasts after Transduction with Adenoviral Bi-Cistronic Vector Carrying Human VEGF165 and Angiopoietin-1. The Journal of Heart and Lung Transplantation, 24, 1393-1402. https://doi.org/10.1016/j.healun.2004.06.004
[27]
Ye, L., Haider, H.Kh., Tan, R.S., et al. (2007) Transplantation of Nanoparticle Transfected Skeletal Myoblasts Overexpressing Vascular Endothelial Growth Factor-165 for Cardiac Repair. Circulation, 116, 113-120. https://doi.org/10.1161/CIRCULATIONAHA.106.680124
[28]
Ye, L., Haider, H.Kh., Tan, R., et al. (2008) Angiomyogenesis Using Liposome Based Vascular Endothelial Growth Factor-165 Transfection with Skeletal Myoblast for Cardiac Repair. Biomaterials, 29, 2125-2137. https://doi.org/10.1016/j.biomaterials.2008.01.014
[29]
Haider, H.K.H., Ye, L., Jiang, S., et al. (2004) Angiomyogenesis for Cardiac Repair Using Human Myoblasts as Carriers of Human Vascular Endothelial Growth Factor. Journal of Molecular Medicine, 82, 539-549. https://doi.org/10.1007/s00109-004-0546-z
[30]
Law, P.K., Law, D.L., Lu, P., et al. (2006) Human Myoblast Genome Therapy. Journal of Geriatric Cardiology, 3, 135-151.
[31]
Rigotti, G., Charles-de-Sá, L., Gontijo-de-Amorim, N.F., et al. (2016) Expanded Stem Cells, Stromal-Vascular Fraction, and Platelet-Rich Plasma Enriched Fat: Comparing Results of Different Facial Rejuvenation Approaches in a Clinical Trial. Aesthetic Surgery Journal, 36, 261-270. https://doi.org/10.1093/asj/sjv231
[32]
Katagiri, T., Yamaguchi, A., Komaki, M., et al. (1994) Bone Morphogenetic Protein-2 Converts the Differentiation Pathway of C2C12 Myoblast into the Osteoblast Lineage. Journal of Cell Biology, 127, 1755-1766. https://doi.org/10.1083/jcb.127.6.1755
[33]
Cheng, W., Law, P., Kwan, H. and Cheng, R. (2014) Stimulation Therapies and the Relevance of Fractal Dynamics to the Treatment of Diseases. Open Journal of Regenerative Medicine, 3, 73-94. https://doi.org/10.4236/ojrm.2014.34009
[34]
Chen, B., Wang, B., Zhang, W.J., Zhou, G. and Cao, Y. (2012) In Vivo Tendon Engineering with Skeletal Muscle Derived Cells in a Mouse Model. Biomaterials, 33, 6086-6097. https://doi.org/10.1016/j.biomaterials.2012.05.022
[35]
Crowley, J.S., Liu, A. and Dobke, M. (2021) Regenerative and Stem Cell-Based Techniques for Facial Rejuvenation. Experimental Biology and Medicine, 246, 1829-1837. https://doi.org/10.1177/15353702211020701
